Glucagon Like Peptide-1-Induced Glucose Metabolism in Differentiated Human Muscle Satellite Cells Is Attenuated by Hyperglycemia

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Green, Charlotte J ^a   Henriksen, Tora I ^a   Pedersen, Bente K ^a   Solomon, Thomas P J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; AGE; ARTICLE; BODY MASS; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE SATELLITE CELL; WESTERN BLOTTING;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLYCOGEN; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; RECEPTORS, GLUCAGON; SATELLITE CELLS, SKELETAL MUSCLE; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84865518871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044284     Document Type: Article

References (42)

1. Gromada J, Ding WG, Barg S, Renstrom E, Rorsman P, (1997) Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Pflugers Arch 434: 515-524.
2. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM, (1998) Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 102: 764-774.
3. Giralt M, Vergara P, (1999) Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 44: 322-329.
4. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, et al. (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276: R1541-R1544.
5. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
6. Chai W, Dong Z, Wang N, Wang W, Tao L, et al. (2012) Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide-Dependent Mechanism. Diabetes 61: 888-896.
7. Yang H, Egan JM, Wang Y, Moyes CD, Roth J, et al. (1998) GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 275: C675-C683.
8. Delgado E, Luque MA, Alcantara A, Trapote MA, Clemente F, et al. (1995) Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16: 225-229.
9. Luque MA, Gonzalez N, Marquez L, Acitores A, Redondo A, et al. (2002) Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 173: 465-473.
10. Acitores A, Gonzalez N, Sancho V, Valverde I, Villanueva-Penacarrillo ML, (2004) Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J Endocrinol 180: 389-398.
11. Alcantara AI, Morales M, Delgado E, Lopez-Delgado MI, Clemente F, et al. (1997) Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 341: 1-7.
12. Gonzalez N, Acitores A, Sancho V, Valverde I, Villanueva-Penacarrillo ML, (2005) Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126: 203-211.
13. Alessi DR, (1997) The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase. FEBS Lett 402: 121-123.
14. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y, (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 23: 5036-5041.
15. Holst JJ, Vilsboll T, Deacon CF, (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297: 127-136.
16. Defronzo RA, Tripathy D, (2009) Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32Suppl 2: S157-S163.
17. Moreno P, Nuche-Berenguer B, Gutierrez-Rojas I, Acitores A, Sancho V, et al. (2012) Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states. J Mol Endocrinol 48: 37-47.
18. Arnes L, Gonzalez N, Tornero-Esteban P, Sancho V, Acitores A, et al. (2008) Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J Mol Med 22: 127-132.
19. Green CJ, Pedersen M, Pedersen BK, Scheele C, (2011) Elevated NF-kappaB activation is conserved in human myocytes cultured from obese type 2 diabetic patients and attenuated by AMP-activated protein kinase. Diabetes 60: 2810-2819.
20. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
21. Broholm C, Brandt C, Schultz NS, Nielsen AR, Pedersen BK, et al. (2012) Deficient leukemia inhibitory factor signaling in muscle precursor cells from patients with type 2 diabetes. Am J Physiol Endocrinol Metab 303: 283-292.
22. Aas V, Hessvik NP, Wettergreen M, Hvammen AW, Hallen S, et al. (2011) Chronic hyperglycemia reduces substrate oxidation and impairs metabolic switching of human myotubes. Biochim Biophys Acta 1812: 94-105.
23. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A, (1992) Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest 90: 1386-1395.
24. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, et al. (2009) The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150: 1155-1164.
25. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, et al. (2007) Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56: 1551-1558.
26. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, et al. (2001) Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50: 2237-2243.
27. Buteau J, Roduit R, Susini S, Prentki M, (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856-864.
28. Buteau J, Spatz ML, Accili D, (2006) Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 55: 1190-1196.
29. Kanzaki M, Mora S, Hwang JB, Saltiel AR, Pessin JE, (2004) Atypical protein kinase C (PKCzeta/lambda) is a convergent downstream target of the insulin-stimulated phosphatidylinositol 3-kinase and TC10 signaling pathways. J Cell Biol 164: 279-290.
30. Wijesekara N, Tung A, Thong F, Klip A, (2006) Muscle cell depolarization induces a gain in surface GLUT4 via reduced endocytosis independently of AMPK. Am J Physiol Endocrinol Metab 290: E1276-E1286.
31. Galante P, Mosthaf L, Kellerer M, Berti L, Tippmer S, et al. (1995) Acute hyperglycemia provides an insulin-independent inducer for GLUT4 translocation in C2C12 myotubes and rat skeletal muscle. Diabetes 44: 646-651.
32. Kawano Y, Rincon J, Soler A, Ryder JW, Nolte LA, et al. (1999) Changes in glucose transport and protein kinase Cbeta(2) in rat skeletal muscle induced by hyperglycaemia. Diabetologia 42: 1071-1079.
33. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, et al. (1994) Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43: 1122-1129.
34. Bandyopadhyay G, Standaert ML, Galloway L, Moscat J, Farese RV, (1997) Evidence for involvement of protein kinase C (PKC)-zeta and noninvolvement of diacylglycerol-sensitive PKCs in insulin-stimulated glucose transport in L6 myotubes. Endocrinology 138: 4721-4731.
35. Standaert ML, Avignon A, Yamada K, Bandyopadhyay G, Farese RV, (1996) The phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits insulin-induced activation of phosphatidylcholine hydrolysis and associated protein kinase C translocation in rat adipocytes. Biochem J 313 (Pt 3): 1039-1046.
36. Baron AD, Brechtel G, Wallace P, Edelman SV, (1988) Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 255: E769-E774.
37. Gao H, Wang X, Zhang Z, Yang Y, Yang J, et al. (2007) GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 32: 90-95.
38. Foley K, Boguslavsky S, Klip A, (2011) Endocytosis, recycling, and regulated exocytosis of glucose transporter 4. Biochemistry 50: 3048-3061.
39. Shi J, Kandror KV, (2005) Sortilin is essential and sufficient for the formation of Glut4 storage vesicles in 3T3-L1 adipocytes. Dev Cell 9: 99-108.
40. Tsuchiya Y, Hatakeyama H, Emoto N, Wagatsuma F, Matsushita S, et al. (2010) Palmitate-induced down-regulation of sortilin and impaired GLUT4 trafficking in C2C12 myotubes. J Biol Chem 285: 34371-34381.
41. Esguerra JL, Bolmeson C, Cilio CM, Eliasson L, (2011) Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat. PLoS One 6: e18613-e18625.
42. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, et al. (2011) MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474: 649-653.